Can molecularly targeted therapy cure patients with resected EGFR mutant NSCLC?

Myron Klevansky, Thomas John

Abstract

In an age of targeted therapies, the promise of eliminating non-targeted and indeed more toxic chemotherapy was considered a given until several trials challenged this assumption.